Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The study found that about 83% achieved a 0.2 reduction in BMI zscore and mean BMI reductions of the 26% for patients with POMC/LEPR deficiencies and of the 10% for BBS
More cases adjudicated as meeting the definition for anaphylaxis occurred in lixisenatide-treated patients (incidence rate of 0.2% or 16 cases per 10,000 patient years) than placebo-treated patient (incidence rate of 0.1% or 7 cases per 10,000 patient years)
GLP 1 Drug Biosimilar Market Size, Share, Trend Report 2026 to 2035 What is GLP 1 Drug Biosimilar Market Size
They are precise
US$ 23.86
US$ 22.35
US$ 28.28
US$ 23.21
US$ 29.62
US$ 23.42
US$ 23.63
US$ 24.75
